CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
China market released 3.0T Magnetic resonance (MR) conditional CIED systemsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06038123
NCT06038123N/ACompleted

China CIED 3.0T MRI Performance Study

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Sep 14, 2023·Updated Jan 14, 2026

In Brief

A clinical study evaluating China market released 3.0T Magnetic resonance (MR) conditional CIED systems for Bradycardia and 2 related conditions. Completed, enrolled 64 participants across 5 sites.

Detailed Summary

The purpose of the China CIED 3.0T MRI Performance Study is to confirm safety of SureScan CIED in the clinical 3.0T MRI environment when subjects receive MRI scans. All subjects will have required follow-up visits at baseline, MRI visit, 1-month post-MRI. The MRI scans will occur at the MRI visit. The MRI scan region will be determined by investigator according to the subject's clinical condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedSep 14, 2023
Enrollment StartNov 28, 2023
Primary CompletionOct 17, 2024
Study CompletionOct 28, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.8 years ago

Interventions

China market released 3.0T Magnetic resonance (MR) conditional CIED systemsdevice

To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)